Glenmark Pharma

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE935A01035
  • NSEID: GLENMARK
  • BSEID: 532296
INR
2,648.00
27 (1.03%)
BSENSE

Nov 20

BSE+NSE Vol: 5.53 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 780863,
    "name": "Glenmark Pharma",
    "stock_name": "Glenmark Pharma",
    "full_name": "Glenmark Pharmaceuticals Ltd.",
    "name_url": "stocks-analysis/glenmark-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "2,648.00",
    "chg": 27,
    "chgp": "1.03%",
    "dir": 1,
    "prev_price": "2,621.00",
    "mcapval": "74,246.00 Cr",
    "mcap": "Mid Cap",
    "scripcode": 532296,
    "symbol": "GLENMARK",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE935A01035",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "5.53 lacs",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/glenmark-pharma-780863-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Glenmark Pharmaceuticals Sees Significant Open Interest Surge Amid Bullish Market Positioning",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-significant-open-interest-surge-amid-bullish-market-positioning-4269741",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/GlenmarkPharmac_oi_spurts_by_underlying_4269741.png",
        "date": "2026-11-20 15:00:37",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a notable surge in open interest in its derivatives segment, signalling increased market participation and potential directional bets. The stock, trading close to its 52-week high, has outperformed its sector and broader indices, reflecting growing investor confidence amid shifting market dynamics."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Significant Open Interest Surge Amid Bullish Market Positioning",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-significant-open-interest-surge-amid-bullish-market-positioning-4269662",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/GlenmarkPharmac_oi_spurts_by_underlying_4269662.png",
        "date": "2026-11-20 14:00:21",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a notable surge in open interest in its derivatives segment, signalling a shift in market sentiment and positioning. The stock’s recent outperformance relative to its sector and the broader Sensex, combined with increased futures and options activity, suggests investors are taking fresh directional bets amid a backdrop of strong technicals and improving fundamentals."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Bullish Market Positioning",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-open-interest-surge-amid-bullish-market-positioning-4269595",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/GlenmarkPharmac_oi_spurts_by_underlying_4269595.png",
        "date": "2026-11-20 13:00:21",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a notable surge in open interest in its derivatives segment, signalling increased market participation and potential directional bets. The stock’s recent performance, coupled with rising volumes and improved technical positioning, suggests a cautiously optimistic outlook for this mid-cap pharmaceutical player."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Significant Open Interest Surge Amid Bullish Market Positioning",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-significant-open-interest-surge-amid-bullish-market-positioning-4269547",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/GlenmarkPharmac_oi_spurts_by_underlying_4269547.png",
        "date": "2026-11-20 12:00:18",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a notable surge in open interest (OI) in its derivatives segment, signalling a shift in market sentiment and positioning. The stock’s open interest rose by 11.4% to 45,940 contracts, up from 41,240, accompanied by robust volume activity and a price performance that outpaced its sector peers. This development suggests increased directional bets and heightened investor interest in the mid-cap pharmaceutical player."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Significant Open Interest Surge Amid Mixed Market Signals",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-significant-open-interest-surge-amid-mixed-market-signals-4268549",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/GlenmarkPharmac_oi_spurts_by_underlying_4268549.png",
        "date": "2026-11-19 15:00:48",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a notable 13.2% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a modest decline in the stock price, the surge in open interest alongside rising volumes suggests evolving directional bets within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Mixed Market Signals",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-open-interest-surge-amid-mixed-market-signals-4268462",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/GlenmarkPharmac_oi_spurts_by_underlying_4268462.png",
        "date": "2026-11-19 14:00:32",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a notable 10.9% increase in open interest in its derivatives segment, signalling heightened market activity and evolving investor positioning. Despite a slight dip in the stock price, the surge in open interest alongside rising delivery volumes suggests a complex interplay of bullish and cautious sentiment among traders."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Positive Price Momentum",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-open-interest-surge-amid-positive-price-momentum-4267256",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/GlenmarkPharmac_oi_spurts_by_underlying_4267256.png",
        "date": "2026-11-18 15:00:38",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a significant surge in open interest in its derivatives segment, signalling a potential shift in market positioning and investor sentiment. The stock outperformed its sector and reversed a four-day decline, supported by robust volume and price action near its 52-week high."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Sharp Open Interest Surge Amid Positive Market Momentum",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-sharp-open-interest-surge-amid-positive-market-momentum-4267170",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/GlenmarkPharmac_oi_spurts_by_underlying_4267170.png",
        "date": "2026-11-18 14:00:30",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a notable 15.0% surge in open interest in its derivatives segment, signalling increased market participation and potential directional bets. This rise accompanies a positive price movement, with the stock closing just 1.87% below its 52-week high, outperforming its sector and reversing a four-day losing streak."
      },
      {
        "title": "Glenmark Pharmaceuticals Sees Significant Open Interest Surge Amid Positive Market Momentum",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/glenmark-pharmaceuticals-sees-significant-open-interest-surge-amid-positive-market-momentum-4267106",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/GlenmarkPharmac_oi_spurts_by_underlying_4267106.png",
        "date": "2026-11-18 13:00:19",
        "description": "Glenmark Pharmaceuticals Ltd. has witnessed a notable 14.05% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. This surge accompanies a positive price trend, with the stock trading close to its 52-week high and outperforming its sector peers, suggesting renewed bullish sentiment in the mid-cap pharmaceutical stock."
      }
    ],
    "total": 191,
    "sid": "780863",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/glenmark-pharmaceuticals-780863"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "17-Nov-2026",
      "details": "Ichnos Glenmark Innovation (IGI) announces IND submission to US FDA for ISB 2301",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "16-Nov-2026",
      "details": "Glenmark Pharmaceuticals Inc. USA Launches Authorised Generic of INLYTA (axitinib) Tablets 1 mg and 5mg",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "09-Nov-2026",
      "details": "Transcript of the Earnings Call",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Glenmark Pharmaceuticals Ltd. has declared <strong>250%</strong> dividend, ex-date: 31 Aug 26",
          "dt": "2026-08-31",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Glenmark Pharmaceuticals Ltd. has announced <strong>1:2</strong> stock split, ex-date: 10 Sep 07",
          "dt": "2007-09-10",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Announcement under Regulation 30 (LODR)-Press Release / Media Release

17-Nov-2026 | Source : BSE

Ichnos Glenmark Innovation (IGI) announces IND submission to US FDA for ISB 2301

Announcement under Regulation 30 (LODR)-Press Release / Media Release

16-Nov-2026 | Source : BSE

Glenmark Pharmaceuticals Inc. USA Launches Authorised Generic of INLYTA (axitinib) Tablets 1 mg and 5mg

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

09-Nov-2026 | Source : BSE

Transcript of the Earnings Call

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Glenmark Pharmaceuticals Ltd. has declared 250% dividend, ex-date: 31 Aug 26

stock-summary
SPLITS

Glenmark Pharmaceuticals Ltd. has announced 1:2 stock split, ex-date: 10 Sep 07

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available